SEC EDGARAUG 122 min read$REPL

Hill Emily Luisa sold $148K of REPL

Hill Emily Luisa (Chief Financial Officer) sold 11,448 shares of Replimune Group, Inc. (REPL) at $12.97 ($0.15M total) on 2026-08-10.

Original reporting

SEC EDGAR · Hill Emily Luisa

Published Aug 12, 2026, 9:06 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 12, 2026, 9:14 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$REPL

Neutral

medium confidence

Mentioned

$REPL

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$REPLNeutralLow

Why it matters

The newest fact is the CFO’s open-market sale details (shares, price, total value, and post-transaction holdings).

Market read

Traders may monitor insider activity for sentiment, but this filing alone does not provide new guidance, trial results, or regulatory developments.

What to watch

The filing does not state motivations, option exercises, or other concurrent transactions; without context, the signal strength is weak.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-12, transaction dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for Replimune Group, Inc.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$REPLNeutralMedium confidence

Context

Replimune CFO Hill Emily Luisa filed a Form 4 selling 11,448 shares at $12.97 on 2026-08-10, totaling $148,480.56.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven rather than driven by new company fundamentals.

Evidence & confidence

The filing discloses transaction details (size, price, post-sale holdings) but provides no new operational, financial, or regulatory information about REPL.

Market effects

Sector

Minimal; insider sales typically do not reset sector expectations without accompanying company-specific news.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be routine for diversification or tax planning, and the absence of a stated 10b5-1 plan does not necessarily imply negative fundamentals.

Key entities

issuer
Replimune Group, Inc.
Subject of the Form 4 insider transaction disclosure.
insider
Hill Emily Luisa
Chief Financial Officer who sold shares.

Read at source ← All news

SEP 11

$MRNAHighAI 9/10

New FDA Drug Approvals - August 2026

The FDA approved 13 drugs in August 2026, including Moderna's mFLUSIVA ($149.56/dose) for influenza prevention, Takeda's Orezyful for narcolepsy, Replimune's Tudriqev ($450,000/course) for melanoma, Bristol-Myers Squibb's Zenbexus ($29,500/28-day cycle) for multiple myeloma, Lantheus' Tauklarify for Alzheimer's diagnosis, and Regeneron's Pasatru for FOP. Each drug showed positive clinical trial results.

finanznachrichten.de3 min

SEP 11

$REPLHighAI 8/10

REPL Stock Tracks Best Day Ever: This Analyst Sees Higher Approval Odds For Replimune’s Melanoma After ‘Overwhelmingly Positive’ Panel Outcome

Replimune Group (REPL) stock surged 140% in pre-market trading after a favorable FDA advisory committee review of its melanoma therapy RP1. Cantor Fitzgerald upgraded REPL to 'Overweight' from 'Neutral', citing an 'overwhelmingly positive' panel outcome. The FDA is expected to make a final decision by Aug. 2, 2026. REPL's stock has fallen 39% year-to-date.

stocktwits.com2 min

SEP 4

$REPLMed

Did FDA’s RP1 Rejection and New Lawsuits Just Shift Replimune Group’s (REPL) Risk Narrative?

Replimune Group (REPL) faces securities class action lawsuits following the FDA's rejection of its RP1 Biologics License Application due to study design issues. The company will discuss its outlook at the Cantor Global Healthcare Conference. Analysts note increased regulatory and legal risks, with shares potentially trading above fair value.

simplywall.st2 min

SEP 3

$REPLHighAI 9/10

FDA Leadership Overrules Staff Concerns To Grant Replimune Accelerated Approval For Tudriqev

Replimune (REPL) received FDA accelerated approval for its cancer therapy Tudriqev, despite staff concerns, after senior FDA leadership intervened. The Oncology Center of Excellence played a key role. Accelerated approval requires confirmatory trials. This marks a significant milestone for Replimune in the competitive oncology market.

londoninsider.co.uk2 min

SEP 2

$REPLHighAI 8/10

Replimune Group stock hits 52-week high at 16.2 USD

Replimune Group Inc (REPL) hit a 52-week high of $16.20, up 165.99% over the past year. Analysts have mixed views, with price targets ranging from $14 to $24. The FDA's approval of its cancer treatment, TUDRIQEV, has drawn positive attention from analysts, with upgrades and increased price targets. The company's earnings report is anticipated to impact stock movement.

investing.com2 min

AUG 27

$REPLLowAI 8/10

ReplimuneÂ Group Lawsuit: Company Asks Court to Dismiss Securities Case Over RP1 FDA Approval Process - TipRanks.com

Replimune Group (NASDAQ: REPL) and its leaders filed a motion to dismiss a lawsuit alleging securities violations over statements about its melanoma treatment RP1's FDA approval process. The investors claim Replimune misled them about FDA feedback on the IGNYTE trial. Replimune argues it disclosed risks and that the FDA ultimately approved RP1 in August 2026.

tipranks.com2 min